| abstract |
Disclosed are Uses of ixabepilone in combination with CYP3A4 inhibitors such as ketoconazole and lapatinib to achieve a surprisingly enhanced pharmacological effect as compared with when ixabepilone is administered unaccompanied by the CYP3A4 inhibitor. Also disclosed are methods of treating cancer in a human patient comprising administering to the human a therapeutically-effective combination of an amount of a the CYP3A4 inhibitor and an amount of ixabepilone to achieve the enhanced pharmacological effect. |